Business Context and Reporting Period
Company: Transcode Therapeutics, Inc. (Nasdaq: RNAZ)
Filing Type: Form 8-K (Current Report)
Date of Report: November 26, 2024 (Event Date); Signed December 2, 2024
Reporting Period: Specific event reporting regarding a private placement and Nasdaq compliance status.
Key Financial Metrics and Capital Structure
Private Placement Details:
- Aggregate Gross Proceeds: Approximately $8 million (before fees and expenses).
- Securities Issued:
- 5,710,000 shares of Common Stock.
- 15,510,160 Pre-Funded Warrants (Exercise Price: $0.0001).
- 21,220,160 Series C Warrants (Initial Exercise Price: $0.475; 5-year term).
- 21,220,160 Series D Warrants (Initial Exercise Price: $0.475; 2.5-year term).
- Offering Price: $0.377 per Share (with warrants) and $0.3769 per Pre-Funded Warrant (with warrants).
- Use of Proceeds: Working capital and general corporate purposes.
Transaction Costs:
- Placement Agent (Benchmark Company LLC): $50,000 cash fee.
- Financial Advisor (A.G.P.): 4.0% of gross proceeds (less $50,000), up to $75,000 for fees/expenses, and a 1% non-accountable expense allowance.
Liquidity and Equity Status:
- The filing states the Company believes it has regained compliance with the Nasdaq Minimum Stockholders' Equity Requirement of $2.5 million as a result of the Private Placement.
- The filing text does not provide specific values for revenue, net income, operating cash flow, or total debt.
Material Changes and Nasdaq Compliance
Nasdaq Listing Status:
- Previous Status: On August 15, 2024, the Company received notice of non-compliance with Nasdaq Listing Rule 5550(b)(1) regarding the $2.5 million minimum stockholders' equity requirement.
- Hearing Outcome: On November 4, 2024, the Nasdaq hearing panel granted an extension until December 31, 2024, to regain compliance.
- Current Status: The Company asserts that the Private Placement has restored stockholders' equity above the $2.5 million threshold. A final compliance determination from Nasdaq is pending.
Lock-Up and Issuance Restrictions:
- The Company agreed not to issue additional Common Stock or equivalents until the later of Shareholder Approval or April 1, 2025.
- A 12-month restriction on Variable Rate Transactions is in effect.
Guidance, Risks, and Contingencies
Shareholder Approval:
- Issuance of shares upon exercise of Common Warrants is subject to Nasdaq rules requiring shareholder approval.
- The Company intends to hold a shareholder meeting within 70 days of the Private Placement closing (December 2, 2024).
Warrant Features and Risks:
- Reset Provisions: Series C and D Warrants include a reset mechanism on specific "Reset Dates" to the lower of the current exercise price or the 10-day VWAP (subject to a $0.0754 floor).
- Cashless Exchange: Series D Warrants allow for a cashless exchange yielding 3.0x the shares issuable on a cash exercise.
- Beneficial Ownership Limits: Exercise is restricted if the holder would own more than 4.99% or 9.99% of outstanding shares.
Delisting Risk:
- Until Nasdaq issues a final determination, there is no assurance of continued listing. Delisting would materially and adversely affect the Company's ability to raise capital.
Investor Verification Checklist
- Nasdaq Compliance Determination: Verify if Nasdaq has officially confirmed the Company's regained compliance with the $2.5 million equity requirement.
- Shareholder Meeting Date: Confirm the scheduled date for the shareholder meeting required to approve the warrant exercises.
- Net Proceeds Calculation: Review the final closing statement to determine exact net proceeds after deducting the 4% A.G.P. fee and other expenses.
- Warrant Exercise Activity: Monitor whether Pre-Funded Warrants or Common Warrants are exercised, as this will impact share count and dilution.
- Registration Statement: Confirm the filing of the registration statement for the resale of securities, which was required within 10 days of November 27, 2024.